Search research articles
Contact Us
Filters
Showing results (511-520 of 565) with videos related to
Page
of 57
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 28, 2023
Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
Arathi Mohan, Kent A Griffith, Fulei Wuchu, et al.
BMC Pharmacology
|
August 18, 2010
Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist
John R Hadcock, Philip A Carpino, Philip A Iredale, et al.
European Journal of Medicinal Chemistry
|
November 9, 2016
Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling
Fabien Plisson, Timothy A Hill, Justin M Mitchell, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 31, 2021
Disease Control After Hypofractionation Versus Conventional Fractionation for Triple Negative Breast Cancer: Comparative Effectiveness in a Large Observational Cohort
Reshma Jagsi, Kent A Griffith, Frank A Vicini, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 17, 2023
6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptor
Gary E Aspnes, Scott W Bagley, Steven B Coffey, et al.
Blood
|
June 6, 2012
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J Jakubowiak, Dominik Dytfeld, Kent A Griffith, et al.
Haematologica
|
June 29, 2014
Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
Dominik Dytfeld, Jagoda Jasielec, Kent A Griffith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2014
Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer
Costanza Paoletti, Maria C Muñiz, Dafydd G Thomas, et al.
The Journal of Organic Chemistry
|
November 7, 2012
Synthesis of spiropiperidine lactam acetyl-CoA carboxylase inhibitors
Kim Huard, Scott W Bagley, Elnaz Menhaji-Klotz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2023
Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA
Reshma Jagsi, Kent A Griffith, Eleanor E Harris, et al.
Page
of 57
Search research articles
Search
Showing results (511-520 of 565) with videos related to
Sort By:
Page
of 57
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 28, 2023
Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
Arathi Mohan, Kent A Griffith, Fulei Wuchu, et al.
BMC Pharmacology
|
August 18, 2010
Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist
John R Hadcock, Philip A Carpino, Philip A Iredale, et al.
European Journal of Medicinal Chemistry
|
November 9, 2016
Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling
Fabien Plisson, Timothy A Hill, Justin M Mitchell, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 31, 2021
Disease Control After Hypofractionation Versus Conventional Fractionation for Triple Negative Breast Cancer: Comparative Effectiveness in a Large Observational Cohort
Reshma Jagsi, Kent A Griffith, Frank A Vicini, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 17, 2023
6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptor
Gary E Aspnes, Scott W Bagley, Steven B Coffey, et al.
Blood
|
June 6, 2012
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J Jakubowiak, Dominik Dytfeld, Kent A Griffith, et al.
Haematologica
|
June 29, 2014
Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
Dominik Dytfeld, Jagoda Jasielec, Kent A Griffith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2014
Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer
Costanza Paoletti, Maria C Muñiz, Dafydd G Thomas, et al.
The Journal of Organic Chemistry
|
November 7, 2012
Synthesis of spiropiperidine lactam acetyl-CoA carboxylase inhibitors
Kim Huard, Scott W Bagley, Elnaz Menhaji-Klotz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2023
Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA
Reshma Jagsi, Kent A Griffith, Eleanor E Harris, et al.
Page
of 57